Forward contract cover locked in for 100% of 2025, 96% of 2026, and 74% of 2027. Maximizing strategic optionality while also returning capital to shareholders. Annualized dividend to increase to $2.50 per Class A Common Share. ATHENS, Greece, Nov. 10, 2025 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE: GSL) (the “Company”, “Global Ship Lease” or “GSL”), an owner of containerships, announced today its unaudited results for the three and nine-month periods ended September 30, 2025. Third Quarter of 2025 and Year to Date Highlights and Other Recent Developments3Q 2025 operating revenue of $192.7 million; up 10.7% on 3Q 2024. 9M 2025 operating revenue of $575.5 million; up 8.9% on 9M 2024.3Q 2025 net income available to common shareholders of $92.6 million, or $2.59 Earnings per Share (EPS); up 17.5% on 3Q 2024. 9M 2025 net...

Released positive Definitive Feasibility Study (“DFS”) for the South West Arkansas Project (“SWA Project”) which continues progressing towards a Final Investment Decision (“FID”) Announced Maiden Inferred Resource for the Company’s first project in East Texas (“Franklin Project”) containing the highest reported lithium-in-brine grades in North America Completed upsized $130 million follow-on offering on the back of strong institutional investor demand and an oversubscribed order book, following quarter closeVANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE.A: SLI), a leading near-commercial lithium company, today announced its financial and operating results for the three and nine-month periods ended September 30, 2025. “We had a busy...

Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 targeted ADC, with ongoing Phase 1 study in China Establised commercial leadership within excutive team with appointment of Brent S. Rice as Chief Commercial Officer Cash and investments of $305.4 million as of September 30, 2025 expected to fund operations into mid-2027NEWTOWN SQUARE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) — ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: “AVBP”), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the third quarter ended September 30, 2025, and highlighted recent Company progress. “Our...

-Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine– -CASGEVY® momentum accelerating; nearly 300 patients have been referred to Authorized Treatment Centers (ATCs), approximately 165 patients have completed their first cell collection and 39 have received infusions across all regions; Vertex expects clear line of sight to over $100 million in total CASGEVY revenue this year and significant growth expected in 2026- -Pediatric development of exa-cel is advancing in SCD and TDT, with enrollment in two global Phase 3 studies completed; initial data will be presented at the upcoming American Society of Hematology (ASH) annual meeting- -Clinical trials ongoing for CTX112™, targeting...

CONTINUED GROWTH AND TRANSFORMATIONAL ACQUISITION RESULT IN EXPANSION TO OVER 5.7 MILLION CONSUMERS(1) SERVED AND $6.6 BILLION IN MANAGED RECEIVABLES(2) ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) — Atlanticus Holdings Corporation (NASDAQ: ATLC) (Atlanticus, the Company, we, our or us), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced its financial results for the third quarter ended September 30, 2025. An accompanying earnings presentation is available in the Investors section of the Company’s website at www.atlanticus.com or by clicking here. Financial and Operating Highlights Third Quarter 2025 Highlights (all comparisons to the Third Quarter 2024)Completed acquisition of Mercury Financial LLC (“Mercury”)...

– Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 –  – Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration – – Ended 3Q25 with cash position of $229 million, maintaining runway into 2028 – LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported third quarter 2025 financial and operating results. “Voyager continues to seek out the optimal modalities for each neurotherapeutic target we pursue. During the third quarter, we shared initial preclinical data on our Voyager NeuroShuttle, a nonviral delivery platform with differentiated...

SINGAPORE, Nov. 10, 2025 (GLOBE NEWSWIRE) — Antalpha Platform Holding Company (NASDAQ: ANTA) (“Antalpha” or the “Company”) today announced its unaudited financial results for the quarter ended September 30, 2025. “Antalpha’s revenue grew 62% year over year in the third quarter. Our accelerating revenue growth and margin expansion underscores the scalability of our Prime lending platform, while capturing increasing demand from Bitcoin-mining financing and new lending scenarios, such as digital asset treasury financing,” said Paul Liang, chief financial officer of Antalpha. “A key driver of Antalpha’s growth is our exposure to the burgeoning crypto market, which plays to Antalpha Prime’s strength of leveraging over-collateralization and other risk-management measures to provide institutions liquidity to navigate...

Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 – $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLOTTE, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced third quarter 2025 financial results, highlighted by IM8’s trajectory towards $120 million in annualized recurring revenue (“ARR”) in just...

Total Revenues Increased 37% with Record Charging Network Revenue of $56 MillionTotal revenue of $92.3 million in the third quarter, representing an increase of 37% year-over-year. Charging network revenue totaled a record $55.8 million in the third quarter, an increase of 33% year-over-year, representing the 15th consecutive quarter of double-digit year-over-year charging revenue growth. Network throughput reached a record 95 gigawatt-hours (“GWh”) in the third quarter, an increase of 25% year-over-year. Added more than 280 new operational stalls during the third quarter. Ended the third quarter with 4,590 stalls in operation, an increase of 25% year-over-year. $201 million in cash, cash equivalents, and restricted cash. Additional borrowing of $41 million received in October.LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) — EVgo...

Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over Year Nine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook for Remainder of 2025 Based on the Company’s Diverse Product Portfolio Supports Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million  Generated $17.9 Million of Cash from Operations During First Nine Months of 2025; as of September 30, 2025, had $72.0 Million of Available Cash Company Continues to Focus on Advancing Business Development Opportunities to Support Continued Long-Term Annual Double-Digit Profitable Growth Interim Futility Analysis of the Pivotal Phase 3 InnovAATe Clinical Trial for the Inhaled AAT Therapy to be Conducted...